“…7,8 Several small studies have reported favorable outcomes after infusion of contaminated products with minimal clinical consequences. [9][10][11] The US Food and Drug Administration (FDA) has recently established new rules for 'current good tissue practice for manufacturers of human cellular and tissue-based products', in which they describe a risk of 2.4% for contamination and raise concerns that there was a high rate of morbidity and mortality after receiving a contaminated product. 12 In this report, we retrospectively studied the outcomes of transplantation involving contaminated HPC product infusions performed during a 6-year period in a single institution.…”